Incremental Value of Genotype Bins over the HAS-BLED Score for the Prediction of Bleeding Risk in Warfarin-Treated Patients with Atrial Fibrillation

Figure 3

Decision curve analyses (DCAs) of the HAS-BLED score alone and the HAS-BLED score combined with genotype bins. This analysis shows the clinical usefulness of theHAS-BLED score alone and the HAS-BLED score combined with genotype bins based on a continuum of potential thresholds for all clinically relevant bleeding events (x-axis) and the net benefit of using the model to stratify AF patients at risk (y-axis) relative to assuming that none of the patients will have a clinically relevant bleeding event. This DCA evaluated the clinical usefulness of the HAS-BLED score combined with genotype bins for all clinically relevant bleeding events in real practice. The use of the HAS-BLED score combined with genotype bins implied a better net benefit than the HAS-BLED score alone.